Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

T Cell Types and Functions01:24

T Cell Types and Functions

966
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
966
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

693
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
693
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

861
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
861

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Validation of the immune-mediated colitis endoscopic score using a retrospective cohort of patients with immune-mediated colitis.

iGIE : innovation, investigation and insights·2026
Same author

Effect of icosapent ethyl treatment on colorectal tissue marine omega-3 polyunsaturated fatty acid levels among patients with a history of adenoma: a prospective, single-arm clinical trial.

The American journal of clinical nutrition·2026
Same author

Autophagy Inhibition Reprograms the Tumor Microenvironment of Pancreatic Cancer to Promote Macrophage Phagocytosis of Tumor Cells.

Cancer research·2026
Same author

Activation-dependent lentiviruses enable antigen-specific T cell expansion and transduction.

bioRxiv : the preprint server for biology·2026
Same author

Dendritic cell redundancy enables priming of anti-tumor CD4<sup>+</sup> T cells in pancreatic cancer.

Cancer cell·2026
Same author

A glucocorticoid-FAS axis controls immune evasion during metastatic seeding.

Nature·2026

関連する実験動画

Updated: Jun 17, 2025

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

8.9K

抗LAG-3はCD8 T細胞エフェクター機能を強化する

Courtney T Kureshi1, Michael Dougan2, Stephanie K Dougan1

  • 1Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA; Program in Immunology, Harvard Medical School, Boston, MA, USA.

Cell
|August 9, 2024
PubMed
まとめ
この要約は機械生成です。

リンパ球活性化遺伝子3 (LAG- 3) を標的とした免疫チェックポイントブロックがPD- 1と組み合わせると,進行性メラノーマの生存率を改善します. マウスとヒトでの新しい研究は,LAG-3に関する重要な洞察を提供します.

さらに関連する動画

Measuring Mitochondrial Function of Na&#239;ve and Effector CD8 T Cells
06:07

Measuring Mitochondrial Function of Naïve and Effector CD8 T Cells

Published on: March 28, 2025

221
In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

5.4K

関連する実験動画

Last Updated: Jun 17, 2025

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

8.9K
Measuring Mitochondrial Function of Na&#239;ve and Effector CD8 T Cells
06:07

Measuring Mitochondrial Function of Naïve and Effector CD8 T Cells

Published on: March 28, 2025

221
In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

5.4K

科学分野:

  • 免疫学
  • 腫瘍学
  • ガン 免疫療法

背景:

  • リンパ球活性化遺伝子3 (LAG-3) は,がんにおける新興の免疫チェックポイント標的である.
  • LAG-3 ブロックは,がん治療に限られた有効性を示しています.

研究 の 目的:

  • 免疫調節におけるLAG-3の役割を調査する.
  • ガン治療におけるLAG-3とPD-1阻害の組み合わせの有効性を評価する.

主な方法:

  • マウスモデルを使った臨床前試験
  • ヒトでの臨床試験のデータ分析

主要な成果:

  • LAG- 3とPD- 1の併用療法により,進行性メラノーマの生存率が著しく改善されます.
  • 研究により,LAG-3の免疫調節機能に関する新しい洞察が得られました.

結論:

  • LAG-3は有望な治療目標であり,特に併用療法では有効です.
  • PD-1と共にLAG-3をターゲットにすると,抗腫瘍免疫反応と臨床結果が改善されます.